The Economic Times

Biocon arm gets positive EMA panel recommendation for breast cancerbiosimilar Pebrilzo

Biocon Biologics has received a positive recommendation from the European Medicines Agencys CHMP for its Pertuzumab biosimilar, Pebrilzo, for HER2-positive breast cancer. The European Commission will take the final decision on marketing authorisation across the EU.